The Defense Health Agency awarded a $472,251.00 Project Grant to Oregon Health & Science University (OHSU) under the Military Medical Research and Development program (CFDA 12.420) to identify novel compounds for the treatment of pPDAchordoma and other SMARCB1-deficient rare tumors. The award period is from August 1, 2023 to July 31, 2026. Through this grant, OHSU will conduct research and development activities to discover and evaluate new drug compounds that could potentially treat these...
The federal Project Grant award of $319,624 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Oregon Health & Science University (OHSU) located in Portland, Oregon. The award supports advanced biomedical research aimed at investigating cell cycle regulators in oligodendrocyte myelination, which is relevant to transforming healthcare for military service members and the broader public. OHSU, a prominent academic...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $999,823 Project Grant to Oregon Health & Science University (OHSU) on June 1, 2024. The grant, titled "TARGETING NEURODEGENERATION IN THE AGED DEMYELINATED CNS," supports OHSU's biomedical research efforts to investigate innovative treatments for neurological disorders. Through this funding, OHSU will conduct basic, applied, and advanced research to develop new medical...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
Oregon Health & Science University was awarded a $494,340 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2022 through July 2025 to elucidate mechanisms of rapid metastatic recurrence in pancreatic ductal adenocarcinoma. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
Oregon Health & Science University was awarded a $385,000 project grant from the Defense Health Agency under the Military Medical Research and Development federal grant program. The two-year grant will support research to investigate the molecular and biological contributions of the SMARCA4 tumor suppressor gene to the formation of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Through basic and applied medical research, the Military Medical Research and Development...
Oregon Health & Science University was awarded a $506,554 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2022 through July 2025 to elucidate mechanisms of rapid metastatic recurrence in pancreatic ductal adenocarcinoma. Through basic, applied, and advanced biomedical research supported by this program, the Army aims to transform military and public health care by...
The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
The Project Grant award for $897,448.00, awarded on June 1, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports Oregon Health & Science University's development of "NEXT-GENERATION ELQS FOR LONG-TERM PROTECTION AGAINST MALARIA." This research initiative aims to advance novel treatments and protective measures against malaria, a key focus area for the Defense Health Agency's military medical research initiatives....
This Project Grant award of $1,401,794.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Oregon Health & Science University (OHSU). The funding will support a 3-year research project investigating the impact of recent childbirth on breast cancer prognosis and tumor molecular phenotypes among young Black and White women. The research aims to enhance understanding of breast cancer disease progression and outcomes in this...